Pharma Pulse 7/18/25: How Parexel Supports Cross Functional Trials for Emerging GLP-1 Therapies; Eisai Explores Novel Dual Mechanism Therapy for Advanced Endometrial Carcinoma

How Parexel Supports Cross Functional Trials for Emerging GLP-1 Therapies

In an interview with Applied Clinical Trials, Shipra Patel, global therapeutic area section head for endocrinology and global head of pediatrics at Parexel, explained how the company supports cross-functional GLP-1 trials by leveraging therapeutic alignment, real-world evidence, and collaborative infrastructure to address growing complexity and expanding indications like Alzheimer disease, addiction, and MASH.

Eisai Explores Novel Dual Mechanism Therapy for Advanced Endometrial Carcinoma

In an interview with Pharmaceutical Executive, Corina Dutcus, SVP and oncology global clinical development lead at Eisai, discussed long-term LEAP-002 trial data for hepatocellular carcinoma and shared updates on Eisai’s novel WNT pathway inhibitor E7386, highlighting its promising combination with lenvatinib in advanced endometrial carcinoma to address significant unmet needs.

Neuriva: A Closer Look at the Efficacy and Safety of this Popular Supplement

Neuriva, a popular brain health supplement combining coffee fruit extract and phosphatidylserine, shows some preliminary cognitive benefits in a short-term clinical trial but lacks robust, long-term evidence on efficacy and safety, highlighting the need for further research and caution in its use.

Research Leaders Across New York State Form Empire State Cellular Therapy Consortium

Five leading research centers across New York State have formed the Empire State Cellular Therapy Consortium to accelerate development, manufacturing, and clinical trials of innovative cell and gene therapies for cancer and other diseases, enhancing patient access to cutting-edge treatments through collaborative resources and expertise.

Below the Surface: Dermatologic Procedures for Hidradenitis Suppurativa

Procedural interventions, including intralesional steroids, deroofing, surgical excision, and laser therapies, play a crucial role alongside medical treatments in managing hidradenitis suppurativa by targeting acute flares and chronic lesions to improve patient outcomes and quality of life.